Ex Parte Tzipori et al - Page 12

                  Appeal  2006-2945                                                                                            
                  Application 10/041,958                                                                                       
                  col. 8, ll. 16-19), whose cells only contain low levels of receptors for SLTs                                
                  (Krivan, col. 8, ll. 25-26) are not being treated – they are being used to                                   
                  produce antibodies that are to be used for passive immunization (Krivan, col.                                
                  8, ll. 31-35), e.g., the treatment of other animals, including humans.                                       
                  Accordingly, we are not persuaded by Appellants’ assertion.                                                  

                  A8.  “Krivan teaches away from treating humans by stating that the method                                    
                  is for the treatment of animals that have few or no receptors to SLTs.                                       
                  Humans have receptors.  That is why cattle and humans are different” (Br.                                    
                  17).                                                                                                         
                          For the foregoing reasons, we disagree with Appellants’ assertion.                                   

                  Perera:                                                                                                      
                  A9.  “Perera does not teach antibodies for therapeutic use and suggests that                                 
                  antibodies to subunits of Stx2 are not as effective as antibodies to Stx1” (Br.                              
                  14).                                                                                                         
                          Appellants are correct in their assertion that Perera does not teach the                             
                  therapeutic use of their antibodies.  Perera does, however, teach five                                       
                  monoclonal antibodies that bind the α-subunit of SLT-II (Perera, page 2130,                                  
                  col. 1, ll. 34-35) and are capable of neutralizing the cytotoxicity of SLT-II                                
                  (Perera abstract).  As the Examiner explains, “[n]eutralizing antibodies, by                                 
                  definition, neutralize the effect of the toxin, consequently motivation to                                   
                  specifically incorporate antibodies with this property would be readily                                      
                  apparent to one of ordinary skill in the art” (Answer 8).  We find no error in                               
                  the Examiner’s assertion.                                                                                    



                                                              12                                                               

Page:  Previous  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  Next

Last modified: September 9, 2013